Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Recursion (Nasdaq: RXRX) announced that CEO & President Najat Khan, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30am PT in San Francisco.
Management will also participate in the 28th Annual Needham Growth Conference on Friday, January 16, 2026. Webcasts will be available in the events section of Recursion Investor Relations at ir.recursion.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RXRX gained 4.12%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $103M to the company's valuation, bringing the market cap to $2.60B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RXRX gained 4.05% while peers were mixed: APGE +2.59%, ARQT +4.03%, IDYA +3.68%, GLPG -0.37%, TVTX -5.15%, suggesting a stock-specific move rather than a broad sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Clinical trial update | Positive | +2.3% | Positive REC-4881 TUPELO Phase 1b/2 efficacy and safety data in FAP. |
| Dec 01 | Event/webinar notice | Neutral | -5.8% | Announcement of webinar for upcoming REC-4881 TUPELO clinical readout. |
| Nov 05 | Earnings report | Negative | -0.8% | Q3 2025 results with lower revenue and large net loss, business update. |
| Nov 05 | Leadership change | Neutral | -0.8% | Board‑approved CEO transition effective January 1, 2026. |
| Nov 04 | Conference participation | Neutral | -8.1% | Announcement of participation in two November 2025 investor conferences. |
Stock often shows negative or mixed reactions around neutral/corporate or conference updates, while clearly positive clinical data and weaker earnings have aligned with modest price moves.
Over the past few months, Recursion has combined clinical, financial, and corporate developments. Positive Phase 1b/2 REC-4881 TUPELO data in FAP on Dec 8, 2025 saw a modest +2.34% move. A webinar announcement for that readout on Dec 1, 2025 coincided with a -5.83% drop. Q3 2025 results on Nov 5, 2025 highlighted lower revenue and a sizable net loss, with the stock down 0.8%. A CEO transition plan and prior November 2025 conference participation each matched small to sharp declines, indicating sensitivity to non‑data corporate news.
Market Pulse Summary
This announcement highlights Recursion’s visibility at major investor events, including the 44th J.P. Morgan Healthcare Conference on January 13, 2026 and the 28th Needham Growth Conference. Historically, similar conference and webinar notices have not always produced durable upside and sometimes coincided with weakness. Against a backdrop of prior earnings-related losses and leadership transition, key items to watch include future clinical readouts, financial updates, and how management frames strategy during these presentations.
AI-generated analysis. Not financial advice.
Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will also participate in the following upcoming investor conference:
- 28th Annual Needham Growth Conference - Friday, January 16, 2026
Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
Investor Contact investor@recursion.com Media Contact media@recursion.com
FAQ
When will Recursion (RXRX) present at the J.P. Morgan Healthcare Conference?
Who from Recursion (RXRX) will present at the January 2026 J.P. Morgan conference?
Will Recursion (RXRX) participate in other investor conferences in January 2026?
Where can investors watch Recursion (RXRX) webcasts for the January 2026 conferences?
What topics will Recursion (RXRX) likely cover in the January 13, 2026 presentation?
How can investors access the Recursion (RXRX) presentation replay after the J.P. Morgan session?
